Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma

A Single Arm, Observational Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment With Sintilimab Injection Plus Endostar in Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

It is a a single arm, observational clinical trial to evaluate the efficacy and safety of combination treatment with sintilimab injection plus endostar in untreated locally advanced or metastatic hepatocellular carcinoma.

Study Overview

• Status: Unknown
• Conditions: Hepatocellular Carcinoma Non-resectable

Detailed Description

For the first line treatment with untreated locally advanced or metastatic hepatocellular carcinoma, sintilimab injection plus endostar might be one of the treatment choices.

• Study Type: Observational
• Enrollment (Anticipated): 2

Contacts and Locations

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China, 430000
      • Recruiting
      • Tongji Hospital
      • Contact: Xianglin Yuan, MD,PHD; Phone Number: 8627-83663406; Email: xlyuan1020@163.com
      • Contact: Yanmei Zou, MD,PHD; Phone Number: 8627-83663406; Email: zouyanmei0101@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Description

Inclusion Criteria:

1. Able and willing to comply with the study plans in this protocol and sign the informed consent;
2. Age of 18-75 years;
3. Cytological or histological diagnosis of untreated locally advanced or metastatic hepatocellular carcinoma;
4. Diseases are not suitable for radical surgery and/or local treatment, or disease progression occurs after surgery and/or local treatment;
5. At least one measurable lesion as defined by RECIST 1.1 criteria and untreated lesion;
6. Patients who have received previous local treatment (e.g., radiofrequency ablation, ethanol or acetic acid injection, cryoablation, high intensity focused ultrasound, transcatheter arterial chemoembolization, transcatheter arterial embolization, etc.) are eligible to participate in the study if the target lesion has not received local treatment before, or if the target lesion within the scope of local treatment has subsequently developed on the basis of RECIST v1.1;
7. ECOG performance status of 0-1;
8. Child-Pugh A;
9. Bone marrow function: absolute neutrophil count(ANC) ≥1.5×109 /L, platelet count(PLT) ≥75×109 /L, hemoglobin(HB) ≥90 g/L;
10. alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤5 x upper limit of normal range (ULN);total bilirubin (TBIL)≤3 x upper limit of normal range (ULN);Creatinine(Cr)≤1.5 x upper limit of normal range(ULN);Serum albumin (> 28 g/L) (2.8 g/dL);Patients not receiving anticoagulation therapy: INR or aPTT < 2 *ULN;Urinary cellulose test paper results Proteinuria < 2 (7 days before the start of treatment);Patients with baseline cellulose test paper urine test results (> 2 proteinuria) should collect 24-hour urine, and then must confirm that the 24-hour urinary protein content is less than 1 g;
11. HIV test results were negative at screening;
12. Records of virological status of hepatitis, confirmed by serological tests of HBV and HCV;
13. Patients with active hepatitis B virus (HBV) infection:HBV DNA < 500 IU/mL was obtained within 28 days before the start of the study, and received at least 14 days of anti-HBV treatment (based on local standard treatment, such as entecavir) prior to the study, and was willing to continue treatment during the study period.

Exclusion Criteria:

1. Systemic HCC treatment has been received in the past;
2. History of primary immunodeficiency is known;
3. It is known to have active tuberculosis;
4. History of allogeneic organ transplantation and hematopoietic stem cell transplantation is known;
5. It is known that there is a history of human immunodeficiency virus (HIV) infection (that is, HIV antibody positive);
6. Severe allergic/allergic reactions to humanized antibodies or fusion proteins were observed;
7. It is known to have hypersensitivity to any component contained in Endor preparations;
8. Initial serious heart disease patients include congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina pectoris, myocardial infarction, severe valvular disease and refractory hypertension;
9. History of PIA meningitis;
10. Major cardiovascular diseases (e.g. New York Heart Association Grade II or more serious heart disease, myocardial infarction or cerebrovascular accident), unstable arrhythmia or unstable angina pectoris, occurred within three months before the start of treatment;
11. Major surgical treatments (except diagnosis) were received within 4 weeks before the start of the study, or major surgical treatments were expected during the study period;
12. Other malignant tumors were diagnosed within 5 years before the first administration. Exceptions included radical basal cell carcinoma, squamous cell carcinoma, adequately treated cervical cancer in situ, and localized prostate cancer;
13. Active infections requiring systemic treatment;
14. Fiberboard HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC are known;
15. Moderate or severe ascites;
16. History of hepatic encephalopathy;
17. Patients with a history of HCV infection but negative results of HCV RNA PCR may consider that they are not infected with HCV;
18. Systemic glucocorticoid therapy or any other form of immunosuppressive therapy is being administered within 7 days prior to the diagnosis of immunodeficiency or the study's first administration; physiological doses of glucocorticoid (<10mg/day prednisone or equivalent) are allowed.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ORR	The rate of participants that achieve either a complete response (CR) or a partial response (PR).	up to 3 years
PFS	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first	up to 3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
OS	Overall survival is defined as time from the start of treatment until death due to any reason.	up to 3 years
Safety as measured by number and grade of adverse events	Summary adverse events according to NCI-CTCAE 4.03	up to 3 years
DOR	The time between the first recorded and objective remission to the first onset of disease progression or all-cause death (whichever happens first)	up to 3 years

Collaborators and Investigators

• Sponsor: Huazhong University of Science and Technology
• Investigators: Study Chair: Xianglin Yuan, MD,PhD, Tongji Hospital

Study record dates

Study Major Dates

• Study Start (Actual): March 5, 2019
• Primary Completion (Anticipated): March 1, 2020
• Study Completion (Anticipated): March 1, 2020

Study Registration Dates

• First Submitted: March 14, 2019
• First Submitted That Met QC Criteria: March 16, 2019
• First Posted (Actual): March 19, 2019

Study Record Updates

• Last Update Posted (Actual): March 19, 2019
• Last Update Submitted That Met QC Criteria: March 16, 2019
• Last Verified: March 1, 2019

More Information

Terms related to this study

• Keywords: Hepatocellular Carcinoma; Endostar; Sintilimab Injection
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Liver Diseases; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular
• Other Study ID Numbers: TJCC009

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No